In the United States will conduct the first clinical trial of various vaccines against coronavirus SARS-CoV-2 in humans: there is already a volunteer. Tests will begin today, March 16, at the Washington-based Kaiser Permanente Health Research Institute in Seattle, writes AP with reference to an anonymous official.
For tests, 45 young and healthy volunteers are recruited. They will be given different doses of vaccines developed by NIH (the US National Institutes of Health has 27 institutes and research centers) and Moderna Inc. People will not get infected: the vaccine does not have the virus itself.
The goal is to ensure that vaccines do not cause disturbing side effects and set the stage for large-scale trials.
Dozens of research groups around the world are now striving to create an effective vaccine. Some doctors are even trying to find a “temporary vaccine”: one that will give protection for a month or two, while a longer protection is being developed.
In April, Inovio Pharmaceuticals announced plans to test vaccines with volunteers: they will be held at the University of Pennsylvania and Kansas City. A similar study will be conducted in China and South Korea. In the PRC, a combination of anti-HIV drugs is being tested on the virus, as well as remdesivir – a drug developed to fight Ebola. In the United States, the University of Nebraska medical center also tests remdesivir in humans with COVID-19.
According to Dr. Anthony Fauci of NIH, even if the first safety tests are successful, “a year and a half will pass” before any vaccine is ready for widespread use.